Eli Lilly and Company (NYSE:LLY) Shares Up 1.3% Following Analyst Upgrade

Eli Lilly and Company (NYSE:LLY)’s share price rose 1.3% on Friday after Rothschild & Co Redburn raised their price target on the stock from $775.00 to $830.00. Rothschild & Co Redburn currently has a neutral rating on the stock. Eli Lilly and Company traded as high as $1,048.57 and last traded at $1,037.84. Approximately 3,297,463 shares were traded during mid-day trading, an increase of 12% from the average daily volume of 2,948,946 shares. The stock had previously closed at $1,024.14.

LLY has been the topic of several other reports. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research note on Monday, December 1st. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Wolfe Research increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Daiwa Capital Markets set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, December 16th. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,162.75.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO David Ricks said impending Medicare coverage for obesity drugs could “change the game” for the launch of Lilly’s oral obesity candidate orforglipron, signaling a major commercial catalyst if access and reimbursement broaden this year. Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
• Positive Sentiment: Lilly announced a $3.5 billion Lehigh Valley (PA) injectable manufacturing plant to produce next‑gen weight‑loss drugs (including retatrutide), expanding U.S. capacity and creating ~2,800 jobs — a material long‑term supply and growth investment. Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
• Positive Sentiment: TD Cowen raised its price target sharply to $1,250 and maintained a buy rating, providing analyst backing that can support further upside and investor confidence. TD Cowen adjusts price target on Eli Lilly and Co to $1,250
• Positive Sentiment: Lilly expanded its R&D and partnering footprint with a ~ $1.93B deal with Repertoire (autoimmune therapies) and other gene‑editing/oncology investments, diversifying future growth drivers beyond GLP‑1s. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Neutral Sentiment: Competitor Novo Nordisk ramped U.S. advertising for Wegovy/Ozempic after prior supply constraints eased, outspending Lilly — a sign of intensifying marketing competition in obesity that could pressure share gains or require higher promotional spend. Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases
• Negative Sentiment: The FDA action date for Lilly’s oral weight‑loss pill orforglipron was moved to April 10 (Q2), delaying potential revenue contribution and near‑term clarity on approval — a timing risk that can cap upside until the new decision date. FDA Decision on Eli Lilly’s Weight Loss Pill Delayed to Q2

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently bought and sold shares of LLY. Secured Retirement Advisors LLC increased its holdings in shares of Eli Lilly and Company by 8.8% during the 4th quarter. Secured Retirement Advisors LLC now owns 1,846 shares of the company’s stock valued at $1,984,000 after acquiring an additional 150 shares during the last quarter. Sigma Planning Corp boosted its position in Eli Lilly and Company by 5.1% during the fourth quarter. Sigma Planning Corp now owns 17,060 shares of the company’s stock worth $18,445,000 after purchasing an additional 825 shares during the period. Belleair Asset Management LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $346,000. Citizens Financial Group Inc. RI raised its position in shares of Eli Lilly and Company by 0.9% in the fourth quarter. Citizens Financial Group Inc. RI now owns 74,935 shares of the company’s stock valued at $80,531,000 after purchasing an additional 648 shares during the period. Finally, North Star Investment Management Corp. lifted its stake in shares of Eli Lilly and Company by 4.4% in the fourth quarter. North Star Investment Management Corp. now owns 8,546 shares of the company’s stock worth $9,185,000 after buying an additional 363 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 1.3%

The company’s fifty day moving average is $1,056.87 and its 200-day moving average is $889.48. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $981.15 billion, a P/E ratio of 50.77, a P/E/G ratio of 0.77 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm posted $1.18 EPS. The business’s quarterly revenue was up 53.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.